A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma

Table 4 Immune responses and clinical outcomes in 8 patients

ID	No. DC injection	DTH	CD4 T cell response	CD8 T cell response	MDSCs*	Tregs*	IL-8^†	Change in Target Lesions (%)	Clinical Response^‡	PFS^§(d)	OS^§(d)	Prognosis
1802	6	+	+	+	decreased	decreased	low	−25.4	SD	173	339	Dead
1803	6	-	+	-	decreased	decreased	low	0	SD	200	353	Dead
1806	6	-	-	-	decreased	no change	high	−18.4	N.A.^¶	100	100	Dead
1808	6	-	-	-	no change	increased	high	−5.4	SD	155	193	Dead
1812	6	-	-	+	no change	no change	low	30.3	PD^#	101	1140^\|\|	Alive
1814	12	+	+	+	decreased	decreased	low	−100	CR	347	1127^\|\|	Alive
1817	6	-	-	-	no change	increased	high	−27.8	PD^**	88	206	Dead
1823	12	+	+	+	decreased	no change	high	−35.3	PR	342^\|\|	342^\|\|	Alive

PFS, progression free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
*Compared to the baseline.
^†High or low is defined as more or less than 60 pg/ml in sera.
^‡4wks after last injection.
^§From the registration (days).
^¶Withdrawn from the study by sudden hypertensive cerebral hemorrhage.
^||A censored case due to the termination of the study.
^#After surgical removal of target lesion (LN metastasis), no recurrence was observed.
^**Though target lesion became smaller, accumulation of pleural effusion was increased.